Radioimmunotargeting of human tumour cells in immunocompetent animals

Fjeld, Jan Gunnar; Bruland, Øyvind S.; Benestad, Haakon B.; Schjerven, L.; Stigbrand, Torgny; Nustad, Kjell

doi:10.1038/bjc.1990.332

Cited by 11 publications

(8 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The artificial tumour model here applied can be used to obtain answers to several fundamental questions in radioimmunotargeting (2)(3)(4)(5). The topic studied in the present paper, i.e.…”

Section: Discussionmentioning

confidence: 99%

“…The DC consists of a plastic ring, with a micropore membrane wall on both sides of the ring. These chambers, filled with antigen-coated polymer particles (2) or viable or fixed tumour cells (3,4), have previously proved useful for immunotargeting purposes. The DCs are implanted in the peritoneal cavity of experimental animals; they are penneable to proteins, including immunoglobulins, whereas the target cells of antigen-coated particles are kept within the DC.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Immunoconjugate Stability in Vivo Measured by Label Release from¹²⁵I Or^99MTc-Antibody Coated Cells Kept in Intraperitoneal Diffusion Chambers in Mice

et al. 1993

View full text Add to dashboard Cite

“…The artificial tumour model here applied can be used to obtain answers to several fundamental questions in radioimmunotargeting (2)(3)(4)(5). The topic studied in the present paper, i.e.…”

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Immunoconjugate Stability in Vivo Measured by Label Release from¹²⁵I Or^99MTc-Antibody Coated Cells Kept in Intraperitoneal Diffusion Chambers in Mice

et al. 1993

View full text Add to dashboard Cite

“…these experiments are regularly far better than in patients. Considering the above-mentioned basic physiological and physiochemical mechanisms that affect the targeting result, it is easy to explain the low tumor uptake in large animals or patients (16). When the antibody distribution volume is large compared with the tumor volume, the fraction of injected dose reaching the tumor will be significantly lower than in a small mouse carrying a relatively large xenograft.…”

Section: Are Labeled Moab 'Magic Bullets'?mentioning

confidence: 99%

Radio‐immunotargeting in experimental animal models of intraperitoneal cancer

Fjeld

Vergote

Vos

et al. 1992

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

The field of immunotargeting, and the challenges met when this technique is applied in experimental animals or in patients, are reviewed. Even with highly specific monoclonal antibodies, non-specific uptake in normal tissues and high background level of unbound radioactivity in blood and extravascular body fluids remain significant problems. Further experimental work in animal model systems is needed to bring this technique from the state of being an experimental method, with limited clinical application, to a routine diagnostic or therapeutic method. Different animal models are available, and their potential for elucidation of the various methodological problems in radio-immunotargeting are discussed in the present paper. In our laboratory. two intraperitoneal models were devised. having relevance for gynecologic and other forms of intraperitoneal malignancies. These models were elaborated with special emphasis on the possibility for exact measurement of important parameters in immunotargeting reactions. In the first model, hybridoma cells are inoculated intraperitoneally to mimic intraperitoneal carcinomatosis, and the monoclonal antibody produced by the hybridoma is used as serum tumor marker. In the second model the tumor cells are contained within intraperitoneally implanted micropore chambers, resembling a localized tumor. An artificial tumor like this allows control with the antigen load in the target, and measurement of the concentration of the injected antibody in the fluid within the target. Hamilton

show abstract

“…A special type of artificial target system has been developed in our laboratory, based on diffusion chambers implanted i.p. in immunocompetent animals (60)(61)(62). Any animal large enough to carry the chamber can be used.…”

Section: Implantation Of Artificial Targetsmentioning

confidence: 99%

Animal Models for Radiolabeled Monoclonal Antibodies in Cancer Research

Aas

Fjeld

1993

Acta Oncologica

View full text Add to dashboard Cite

Radioimmunotargeting of human tumour cells in immunocompetent animals

Cited by 11 publications

References 9 publications

Immunoconjugate Stability in Vivo Measured by Label Release from¹²⁵I Or^99MTc-Antibody Coated Cells Kept in Intraperitoneal Diffusion Chambers in Mice

Immunoconjugate Stability in Vivo Measured by Label Release from¹²⁵I Or^99MTc-Antibody Coated Cells Kept in Intraperitoneal Diffusion Chambers in Mice

Radio‐immunotargeting in experimental animal models of intraperitoneal cancer

Animal Models for Radiolabeled Monoclonal Antibodies in Cancer Research

Contact Info

Product

Resources

About

Radioimmunotargeting of human tumour cells in immunocompetent animals

Cited by 11 publications

References 9 publications

Immunoconjugate Stability in Vivo Measured by Label Release from125I Or99MTc-Antibody Coated Cells Kept in Intraperitoneal Diffusion Chambers in Mice

Immunoconjugate Stability in Vivo Measured by Label Release from125I Or99MTc-Antibody Coated Cells Kept in Intraperitoneal Diffusion Chambers in Mice

Radio‐immunotargeting in experimental animal models of intraperitoneal cancer

Animal Models for Radiolabeled Monoclonal Antibodies in Cancer Research

Contact Info

Product

Resources

About

Immunoconjugate Stability in Vivo Measured by Label Release from¹²⁵I Or^99MTc-Antibody Coated Cells Kept in Intraperitoneal Diffusion Chambers in Mice

Immunoconjugate Stability in Vivo Measured by Label Release from¹²⁵I Or^99MTc-Antibody Coated Cells Kept in Intraperitoneal Diffusion Chambers in Mice